Almac Introduces Qualified Person Facilitation Program for Conducting Trials in the European Union
Program designed to simplify and expedite the QP release process
Almac is pleased to announce the Qualified Person (QP) Facilitation Program; a value-add enhancement to Almac’s current suite of QP services. Offered to global clients importing investigational medicinal products (IMP) into the European Union for clinical trial, this solution has been developed to alleviate the complex logistical challenges surrounding the QP Release process as well as provide a deeper level of consulting during this critical stage of clinical trial distribution.
This latest addition to the Almac portfolio is complementary to the already extensive range of services including packaging, labelling and global distribution of clinical supplies. Directly, the on-site QP Facilitation Programme enhances Almac’s QP services portfolio which currently includes regulatory guidance, global auditing and import testing. To simplify and expedite the often complicated QP Release process, an Almac Quality Compliance Manager will be placed at the client site in order to explain the release processes and to clearly define the responsibilities for both the sponsor and Almac.
Features of the program include access to a dedicated Quality Compliance Manager on-site that provides supply chain assessment, assembly and completion of relevant documentation necessary for QP Release, and an overall better understanding of all information pertaining to the QP release process. In addition to reducing the burden of handling this process internally, clients will receive unique, study specific guidance from an experienced Quality Compliance Manager who is an expert in the QP Release process.
“The QP Facilitation Programme, through face-to-face interaction, will work to eliminate issues with the QP Release process and effectively remove the preparation for QP Release from the critical path,” said Paul O’Connor, Global Vice President Quality at Almac. “We believe this service to be a tremendous benefit to clients with limited internal resources or those unfamiliar with the QP Release process.”
By participating in the QP Facilitation Programme, Almac clients will find the QP Release process more straightforward and accomplish necessary documentation in a more timely fashion.
Almac will be exhibiting at the 48th DIA annual meeting in Philadelphia, booth # 2525 and can provide more information on Almac’s QP services and the entire clinical trial supply service portfolio, alternatively, please contact clinicalservices@almacgroup.com.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
